Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms
The Growth Op, December 13, 2021
Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.
Psychedelics for mental illness
ABC News, December 12, 2021
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.
‘This isn’t the 60s again’: psychedelics business takes off amid culture clash
The Guardian, December 12, 2021
Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.
Psychedelics can change humanity for the better. It’s time to unlock their power
The Guardian, November 26, 2021
Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.
Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia
ABC News, November 12, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Monash presses go on psychedelics to tackle ‘mental health tsunami’
The Sydney Morning Herald, November 10, 2021
Monash University has set its sights on capturing a slice of the multibillion dollar psychedelic medicines market, with the launch of a drug development centre for new psychiatric treatments, including those using MDMA and psilocybin.
New research brings psychedelic drugs a step closer to medical use
ABC - RN Breakfast with Fran Kelly, November 10, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Major announcement: COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Globe News Wire, November 9, 2021
Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support.
Will the magic of psychedelics transform psychiatry?
The Guardian, November 7, 2021
Imagine a medicine that could help people process disturbing memories, sparking behavioural changes rather than merely burying and suppressing symptoms and trauma.
New research shows how psychedelic medicines can help people with PTSD
Today.com, November 5, 2021
TODAY’s Savannah Guthrie spoke to two patients whose lives have been changed by the therapy.
World-first trial of psilocybin therapy for anxiety disorders to begin in Australia
Happymag, November 1, 2021
Incannex Healthcare, in partnership with Monash University, has obtained ethics approval to begin the first-ever clinical trial investigating the effects of psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD).
Johns Hopkins Receives $4M From NIH To Study Psilocybin As Tool To Quit Smoking
Ganjapreneur, October 22, 2021
Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.
DEA Wants Way More Cannabis & Psychedelics for Research In 2022
Ganjapreneur, October 18, 2021
The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.
Psychedelic research renaissance: The urgent quest for new mental health medicines
Lens Monash, October 15, 2021
“There’s been a resurgence in research and interest in psychedelic medicine over the past two decades, and particularly so over the past five years,” says Dr Liknaitzky.
Could mushrooms, molly and acid be the new wave of mental health care?
NBC News, October 13, 2021
Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.
What if a Pill Can Change Your Politics or Religious Beliefs?
Scientific American, October 11, 2021
A new mental health treatment using the psychedelic compound psilocybin raises questions about medicine and values.
National anxiety crisis worsens
The Australian, October 3, 2021
Australians are reporting depression, anxiety and stress at higher rates than the same time last year, with four in five experiencing poor mental health, and children and young people the most seriously affected, as pandemic uncertainty and lockdowns continue to take a toll.
Psychedelic biotech Psylo raises first funds
The Australian, October 1, 2021
There’s a growing pool of funds being invested in psychedelic research.
Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of childhood abuse
Psypost, September 30, 2021
The use of psychedelic medicines is associated with lower levels of complex posttraumatic stress symptoms and internalized shame in adults who suffered maltreatment in childhood, according to new research published in the journal Chronic Stress.
Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
Newsweek, September 22, 2021
Psilocybin could be the biggest advance since Prozac.